• Protease Inhibitor Cocktail EDTA-Free: Safeguarding Proteomi

  2026-05-26

  Discover how the Protease Inhibitor Cocktail EDTA-Free advances protein extraction and cellular assays. This deep dive explores inhibitor selection, lysosomal repair insights, and workflow optimization for proteomic fidelity.

• NADH in Mitochondrial Electron Transport Chain Research

  2026-05-26

  Reduced nicotinamide adenine dinucleotide (NADH) is indispensable for dissecting mitochondrial energy metabolism and probing redox states in both disease models and advanced therapeutic strategies. This guide details actionable workflows, troubleshooting insights, and the translation of recent redox imbalance findings into robust experimental design.

• Ademetionine (SAMe) in Neurological Disorders: Clinical Insi

  2026-05-25

  This review synthesizes the mechanistic and clinical roles of ademetionine (S-adenosylmethionine; SAMe) in neurological and psychiatric disorders, emphasizing its function as a central methyl donor and its potential to alleviate symptoms in conditions such as depression and dementia. The findings highlight the importance of methylation reactions in CNS health and the promise of SAMe as a pharmacological intervention for neuropsychiatric complications linked to methylation deficits.

• Doxycycline: Advancing Tetracycline Antibiotic Research Work

  2026-05-25

  Doxycycline’s dual role as an antimicrobial and broad-spectrum metalloproteinase inhibitor makes it indispensable for translational research in cancer, vascular biology, and cell fate studies. This article distills actionable protocols, troubleshooting expertise, and workflow innovations—empowering scientists to fully leverage APExBIO’s validated Doxycycline for high-impact discoveries.

• PDHA1 Succinylation Drives Immune Evasion in Cholangiocarcin

  2026-05-24

  This study uncovers how succinylation of PDHA1 at lysine 83 in cholangiocarcinoma cells facilitates immune evasion by promoting α-ketoglutaric acid accumulation and suppressing macrophage antigen presentation. Inhibiting this modification with CPI-613 enhances chemotherapy efficacy, suggesting a promising approach to overcome drug resistance in this aggressive cancer.

• EV-Transferred ACLY Drives TAM Differentiation in Liver Canc

  2026-05-23

  This study reveals how extracellular vesicles (EVs) from hepatocellular carcinoma (HCC) cells deliver ATP-citrate lyase (ACLY) to monocytes, inducing their differentiation into immunosuppressive tumor-associated macrophages (TAMs). The findings establish EV-mediated ACLY transfer as a critical metabolic mechanism of immune evasion in HCC and highlight targeted ACLY inhibition as a promising strategy to enhance immunotherapy.

• TAK-242 (Resatorvid): Advancing TLR4 Inhibition in Neuroinfl

  2026-05-22

  Explore how TAK-242 (Resatorvid) empowers advanced neuroinflammation research through specific TLR4 pathway inhibition. This in-depth analysis uniquely connects mechanistic insights, translational assay design, and the latest neuroimmune findings.

• Precision Protease Inhibition: Advancing Lysosome Research

  2026-05-22

  This thought-leadership article explores how EDTA-free, DMSO-based protease inhibitor cocktails are transforming protein extraction and lysosome research. Integrating mechanistic insights from recent studies on lysosomal repair, it offers strategic guidance for translational researchers, highlights experimental best practices, and positions APExBIO's Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) as an essential solution for preserving protein integrity in advanced workflows.

• EV-Transferred ACLY Drives TAM Differentiation and HCC Progr

  2026-05-21

  This study demonstrates that hepatocellular carcinoma (HCC) cells secrete extracellular vesicles (EVs) containing ATP-citrate lyase (ACLY), which are internalized by monocytes and drive their differentiation into immunosuppressive tumor-associated macrophages (TAMs). The findings reveal a novel metabolic mechanism of immune evasion in HCC and support targeted inhibition of EV-delivered ACLY as a strategy to enhance immunotherapy efficacy.

• 3D Spheroid Models Advance Organ-Confined Prostate Cancer Re

  2026-05-21

  This study demonstrates the generation and characterization of patient-derived 3D spheroid cultures from radical prostatectomy specimens, enabling more accurate in vitro modeling of organ-confined prostate cancer. The innovation provides a robust platform for drug testing and translational research, with important implications for preclinical studies targeting androgen signaling.

• KPT-330 (Selinexor): Applied CRM1 Inhibition in Cancer Resea

  2026-05-20

  KPT-330 (Selinexor) is redefining cancer research by enabling precise nuclear export inhibition, apoptosis induction, and synergistic therapy design. Discover actionable workflows, troubleshooting strategies, and translational advances that set this oral CRM1 inhibitor apart for experimental and preclinical use.

• D-Luciferin in Metastasis Research: Precision Bioluminescenc

  2026-05-20

  Explore D-Luciferin as a firefly luciferase substrate advancing metastasis research, with a focus on its integration into quantitative bioluminescence imaging of oncogenic pathways. Discover unique assay considerations, protocol details, and new insights from recent colorectal cancer studies.

• Viral Disruption of Ferroportin-1 Undermines Host Iron Withh

  2026-05-19

  The referenced study uncovers how viruses promote degradation of the iron exporter FPN1, leading to elevated intracellular iron that impairs innate antiviral responses. These findings clarify a previously uncharacterized mechanism by which viruses circumvent host iron withholding, highlighting the central role of FPN1 in immune defense.

• Tin Mesoporphyrin IX (chloride): Reliable Heme Oxygenase Inh

  2026-05-19

  This article explores practical laboratory scenarios where Tin Mesoporphyrin IX (chloride) (SKU C5606) delivers reproducible, data-backed solutions for heme oxygenase inhibition in metabolic and antiviral research. Scenario-driven Q&A blocks address assay optimization, data interpretation, and vendor reliability, positioning APExBIO’s C5606 as a trusted choice for advanced cell-based workflows.

• Strategic ATM Kinase Inhibition: KU-60019 in Translational R

  2026-05-18

  Explore the mechanistic foundations and translational impact of KU-60019, a next-generation ATM kinase inhibitor, in sensitizing glioma and other cancers to genotoxic therapies. This article uniquely integrates recent lncRNA-mediated regulation insights with actionable, evidence-backed protocol strategies and workflow guidance.

497 records 13/34 page Previous Next First page 上5页 1112131415 下5页 Last page